Suzuki, Motohiro
Ishibashi, Satoru
Iwasawa, Eri
Oguma, Takahiro
Saito, Yasuhiro
Li, Fuying
Otsu, Shinichi
Ichinose, Keiko
Yoshioka, Kotaro
Nagata, Tetsuya
Yokota, Takanori
Funding for this research was provided by:
Grant-in-Aid for Scientific Research (17H01548)
Grant-in-Aid for Scientific Research (26282136)
Science and Technology Platform Program for Advanced Biological Medicine (20am0401006h0002)
Basic Science and Platform Technology Program for Innovative Biological Medicine (18am0301003h0005)
Article History
Received: 6 November 2020
Accepted: 11 June 2021
First Online: 9 July 2021
Competing interests
: Funding: All work presents results of a joint research program with Mitsubishi Tanabe Pharma Corporation. Employment: T. O. and Y. S. are employees of Mitsubishi Tanabe Pharma Corporation. Personal financial interests: T.Y. is collaborating with Daiichi Sankyo Co., Ltd. (Tokyo, Japan), NanoCarrier Co., Ltd. (Chiba, Japan), Ono Pharmaceutical Co., Ltd. (Osaka, Japan), Rena Therapeutics Inc. (Tokyo, Japan), Takeda Pharmaceutical Co., Ltd. (Tokyo, Japan), Toray Industries Inc. (Tokyo, Japan), PST Inc. (Yokohama, Japan), AGC Inc. (Tokyo, Japan), and Ionis Pharmaceuticals (CA, USA). T.Y. has consulted for Sumitomo Dainippon Pharma Co., Ltd. (Osaka, Japan), Teijin Pharma Limited. (Tokyo, Japan), Rena Therapeutics Inc. (Tokyo, Japan), and Braizon Therapeutics Inc. (Tokyo, Japan). The other authors declare no competing interests. Patents and patent applications: patent applicant: Tokyo Medical and Dental University; Inventors: Takanori Yokota, and Satoru Ishibashi; Application number: PCT/JP2019/007,458; Status of application: patent application pending; Specific aspect of manuscript covered in patent application: application of heteroduplex oligonucleotide to ischemic stroke.